Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes
Fabio Nascimbeni, Elisa Pellegrini, Simonetta Lugari, et al.
Atherosclerosis (2019) Vol. 284, pp. 66-74
Closed Access | Times Cited: 74

Showing 26-50 of 74 citing articles:

From Liver Fat to Cancer: Perils of the Western Diet
Ju Youn Kim, Feng He, Michael Karin
Cancers (2021) Vol. 13, Iss. 5, pp. 1095-1095
Open Access | Times Cited: 30
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
Anna Michelotti, Marco de Scordilli, Lorenza Palmero, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 2034-2034
Open Access | Times Cited: 30
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Tieshan Teng, Shuai Qiu, Yiming Zhao, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7841-7841
Open Access | Times Cited: 19
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Exploring Systemic Impacts and Innovative Therapies
Parag Jain, Akanksha Jain, Rohitas Deshmukh, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102584-102584
Closed Access
Beyond Medication: Unveiling the Role of Diet and Lifestyle in Fatty Liver Disease Management
Iahtisham-Ul-Haq, Muhammad Shahid Nadeem, Aanchal Sharma, et al.
Human Nutrition & Metabolism (2025), pp. 200317-200317
Open Access
The Potential Role of C-Reactive Protein in Metabolic-Dysfunction-Associated Fatty Liver Disease and Aging
Zheng Ding, Yuqiu Wei, Jing Peng, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2711-2711
Open Access | Times Cited: 10
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
George Agyapong, Farzaneh Dashti, Bubu A. Banini
Annals of the New York Academy of Sciences (2023) Vol. 1526, Iss. 1, pp. 16-29
Open Access | Times Cited: 9
The Fibrosis-5 Index Predicts Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Senjiang Chen, Bouwei Zhu, Zan Luo, et al.
Angiology (2024)
Closed Access | Times Cited: 3
NAFLDin type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews (2020) Vol. 37, Iss. 2
Closed Access | Times Cited: 23
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need
Giovanni Guaraldi, James Maurice, Catia Marzolini, et al.
Hepatology (2020) Vol. 71, Iss. 5, pp. 1831-1844
Closed Access | Times Cited: 22
Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial
Shahin Merat, Elham Jafari, Amir Reza Radmard, et al.
European Heart Journal (2021) Vol. 43, Iss. 21, pp. 2023-2033
Open Access | Times Cited: 18
Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!
Theocharis Koufakis, Djordje S. Popovic, Christodoulos Papadopoulos, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 2, pp. 123-126
Open Access | Times Cited: 2
Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
Anita M. van den Hoek, Lars Verschuren, Martien Caspers, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Statin use and development and progression of non-alcohol fatty liver disease based on ultrasonography: a cohort study
Baoyu Feng, Fengde Li, Yanqi Lan, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 2
Impact of Rosuvastatin on Metabolic Syndrome Patients with Moderate to Severe Metabolic Associated Fatty Liver Disease without Overt Diabetes: A Randomized Clinical Trial
Xuan Wang, Lu Lyu, Wei Li, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 9, pp. 103126-103126
Open Access | Times Cited: 2
Beneficial Activities of Alisma orientale Extract in a Western Diet-Induced Murine Non-Alcoholic Steatohepatitis and Related Fibrosis Model via Regulation of the Hepatic Adiponectin and Farnesoid X Receptor Pathways
Seung Ho Jeon, Eungyeong Jang, Geonha Park, et al.
Nutrients (2022) Vol. 14, Iss. 3, pp. 695-695
Open Access | Times Cited: 10
New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective
Niki Katsiki, Ele Ferrannini, Christos S. Mantzoros
Metabolism (2020) Vol. 107, pp. 154218-154218
Closed Access | Times Cited: 15
Choosing statins: a review to guide clinical practice
Roberta de Pádua Borges, Nathália Abi Habib Degobi, Marcello Casaccia Bertoluci
Archives of Endocrinology and Metabolism (2020)
Open Access | Times Cited: 15
Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells
Álvaro Cerda, Raul Hernandes Bortolin, Victor Manríquez, et al.
Pharmacological Reports (2021) Vol. 73, Iss. 3, pp. 868-880
Closed Access | Times Cited: 12
Effect of theaflavin-3,3′-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARδ/Fabp4 axis and gut microbiota
Cheng Zhou, Wenji Zhang, Hui Lin, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 8
Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy
Elisabetta Bugianesi, Luca Miele, Giovanna Donnarumma, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 185-200
Open Access | Times Cited: 1
Statin therapy is associated with lower risk of mortality among liver transplant candidates with metabolic dysfunction associated steatohepatitis
Katherine M. Cooper, Ami Patel, Christopher Zammitti, et al.
Journal of Clinical and Experimental Hepatology (2024) Vol. 15, Iss. 2, pp. 102427-102427
Closed Access | Times Cited: 1
Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management
Fajuan Rui, Hongli Yang, Xinyu Hu, et al.
Infectious Microbes & Diseases (2022) Vol. 4, Iss. 2, pp. 49-55
Open Access | Times Cited: 7
Folate Metabolism in Hepatocellular Carcinoma. What Do We Know So Far?
Jaqueline Quevedo-Ocampo, Alejandro Escobedo‐Calvario, Verónica Souza-Arroyo, et al.
Technology in Cancer Research & Treatment (2022) Vol. 21
Open Access | Times Cited: 7
Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents
Michael Doulberis, Stergios A. Pοlyzos, Apostolis Papaefthymiou, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 3, pp. 247-251
Open Access | Times Cited: 10

Scroll to top